Exaggerated risk perception of asbestos-related diseases: commentary
https://doi.org/10.18699/SSMJ20230201
Abstract
Health risks from asbestos have been evaluated on the basis of professional histories from remote past, when exposures at workplaces were greater than today. The linear no-threshold model has been applied, although its relevance has not been demonstrated. Fibers are often found in the lungs and pleura at post mortem examinations. The fnding of fbers does not prove that a disease was caused by asbestos. It can be reasonably assumed that targeted search for mesothelioma and other asbestos-related diseases in exposed people resulted in increased detection rate. Histological and immunochemical characteristics of malignant mesothelioma partly overlap with other cancers, which may contribute to overdiagnosis in exposed populations. Amphibole asbestos is more toxic than chrysotile but there are discrepancies between experimental and epidemiological data. The promising way to obtain reliable information is lifelong animal experiments. Asbestos bans applied in some countries are excessive and should be reconsidered on the basis of independent research. It can be reasonably assumed that non-use of asbestos-containing brakes, freproofng, and insulation increases the harm from fres, armed conflicts and trafc accidents.
About the Author
S. V. Jargin
Peoples’ Friendship University of Russia
Russian Federation
Russian Federation
Sergei V. Jargin, candidate of medical sciences
117198, Moscow, Miklukho-Maklaya str., 6
References
1. Jargin S.V. Anti-asbestos campaign and common sense. Molodoy uchenyy = Young Scientist. 2013;9(56):490–495. [In Russian].
2. Jargin S.V. Asbestos and mesothelioma: A comment. Indian J. Occup. Environ. Med. 2018;22(2):113–114. doi: 10.4103/ijoem.IJOEM_49_18
3. Jargin S.V. Asbestos, mesothelioma and lung cancer: A comment. Galore International Journal of Health Sciences and Research. 2017;2(4):19–29
4. Malinconico S., Paglietti F., Serranti S., Bonifazi G., Lonigro I. Asbestos in soil and water: A review of analytical techniques and methods. J. Hazard Mater. 2022;436:129083. doi: 10.1016/j.jhazmat.2022.129083
5. Berry T.A., Belluso E., Vigliaturo R., Gieré R., Emmett E.A., Testa J.R., Steinhorn G., Wallis S.L. Asbestos and other hazardous fbrous minerals: potential exposure pathways and associated health risks. Int. J. Environ. Res. Public Health. 2022;19(7):4031. doi:10.3390/ijerph19074031
6. Neiman S.M., Vezentsev A.I., Kashansky S.V. On the safety of asbestos-cement materials and products. Moscow: Building Materials, 2006. 63 p. [In Russian].
7. Yanin E.P. Asbestos in the environment. Moscow: IMGRE, 1997. 177 p.
8. Noonan C.W. Environmental asbestos exposure and risk of mesothelioma. Ann. Transl. Med. 2017;5(11):234. doi: 10.21037/atm.2017.03.74
9. Ilgren E., van Orden D.R., Lee R.J., Kamiya Y.M., Hoskins J.A. Further studies of Bolivian crocidolite – Part IV: Fibre width, fbre drift and their relation to mesothelioma induction: Preliminary fndings. Epidemiology Biostatistics and Public Health. 2015;12:e11167-1. doi: 10.2427/11167
10. Casali M., Carugno M., Cattaneo A., Consonni D., Mensi C., Genovese U., Cavallo D.M., Somigliana A., Pesatori A.C. Asbestos lung burden in necroscopic samples from the general population of Milan, Italy. Ann. Occup. Hyg. 2015;59(7):909–921. doi:10.1093/annhyg/mev028 11. Bayram M., Bakan N.D. Environmental exposure to asbestos: from geology to mesothelioma. Curr. Opin. Pulm. Med. 2014;20(3):301–307. doi: 10.1097/MCP.0000000000000053
11. Yang H., Testa J.R., Carbone M. Mesothelioma epidemiology, carcinogenesis, and pathogenesis. Curr. Treat. Options Oncol. 2008;9(2-3):147–157. doi:10.1007/s11864-008-0067-z
12. Wolff H., Vehmas T., Oksa P., Rantanen J., Vainio H. Asbestos, asbestosis, and cancer, the Helsinki criteria for diagnosis and attribution 2014: recommendations. Scand. J. Work Environ. Health. 2015;41(1):5–15. doi: 10.5271/sjweh.3462
13. Rossini M., Rizzo P., Bononi I., Clementz A., Ferrari R., Martini F., Tognon M.G. New perspectives on diagnosis and therapy of malignant pleural mesothelioma. Front. Oncol. 2018;8:91. doi: 10.3389/fonc.2018.00091
14. Røe O.D., Anderssen E., Helge E., Pettersen C.H., Olsen K.S., Sandeck H., Haaverstad R., Lundgren S., Larsson E. Genome-wide profle of pleural mesothelioma versus parietal and visceral pleura: the emerging gene portrait of the mesothelioma phenotype. PLoS One. 2009;4(8):e6554. doi: 10.1371/journal.pone.0006554
15. Tomasetti M., Amati M., Santarelli L., Alleva R., Neuzil J. Malignant mesothelioma: biology, diagnosis and therapeutic approaches. Curr. Mol. Pharmacol. 2009;2(2):190–206. doi: 10.2174/1874467210902020190
16. Carbone M., Gazdar A., Butel J.S. SV40 and human mesothelioma. Transl. Lung Cancer Res. 2020;9(Suppl 1):S47–S59. doi: 10.21037/tlcr.2020.02.03
17. Rotondo J.C., Mazzoni E., Bononi I., Tognon M., Martini F. Association between simian virus 40 and human tumors. Front. Oncol. 2019;9:670. doi: 10.3389/fonc.2019.00670
18. Mazzoni E., Bononi I., Rotondo J.C., Mazziotta C., Libener R., Guaschino R., Gafà R., Lanza G., Martini F., Tognon M. Sera from patients with malignant pleural mesothelioma tested positive for IgG antibodies against SV40 large t antigen: the viral oncoprotein. J. Oncol. 2022;2022:7249912. doi: 10.1155/2022/7249912
19. Garcea R.L., Imperiale M.J. Simian virus 40 infection of humans. J. Virol. 2003;77(9):5039–5045. doi: 10.1128/jvi.77.9.5039-5045.2003
20. Cicala C., Pompetti F., Carbone M. SV40 induces mesotheliomas in hamsters. Am. J. Pathol. 1993;142(5):1524–1533.
21. Carbone M., Adusumilli P.S., Alexander H.R. Jr., Baas P., Bardelli F., Bononi A., Bueno R., Felley-Bosco E., Galateau-Salle F., Jablons D., …Pass H.I. Mesothelioma: Scientifc clues for prevention, diagnosis, and therapy. CA Cancer J. Clin. 2019;69(5):402–429. doi: 10.3322/caac.21572
22. Saludes V., Esteve M., Casas I., Ausina V., Martró E. Hepatitis C virus transmission during colonoscopy evidenced by phylogenetic analysis. J. Clin. Virol. 2013;57(3):263–266. doi: 10.1016/j.jcv.2013.03.007
23. Milishnikova V.V., Loshchilov I.Yu., Gladkova E.V., Aksenova A.O., Turkina L.A. Endoscopic and morphological characteristics of the bronchi and lungs in asbestosis and dust-induced bronchitis in asbestos-textile industry workers. Gigiyena truda i professional’nyye zabolevaniya = Occupational Health and Occupational Diseases. 1990;(7):19–22. [In Russian].
24. Likhacheva E.I., Iarina A.L., Vagina E.R., Klimina M.S., Obukhova T.I., Dovgolyuk T.A., Kashanskii S.V. Clinical features of pulmonary diseases caused by chrysotile asbestos dust. Meditsina truda i promyshlennaya ekologiya = Occupational Medicine and Industrial Ecology. 2000;(11):30–33. [In Russian].
25. Elovskaya L.T., Gurvich E.B., Gladkova E.V., Elfmov A.I. Occupational health and health status of workers in enterprises that mine and use asbestos. Moscow: VNIIESM; 1991. 74 p. [In Russian].
26. Kazantsev V.A. The use of bronchological sanation for treatment of community-acquired pneumonia. Russian Respiratory Society. 14th National Congress of Lung diseases: proc. congr., Moscow, 2004 June 22–26. M., 2004. P. 361. [In Russian].
27. Ismagilov N.M. Complicated community-acquired pneumonia in young people from organized groups: clinical and morphological picture, diagnosis and treatment: аbstract of thesis… cand. med. sci. Samara, 2009. 23 p. [In Russian].
28. Paustenbach D., Brew D., Ligas S., Heywood J. A critical review of the 2020 EPA risk assessment for chrysotile and its many shortcomings. Crit. Rev. Toxicol. 2021;51(5):509–539. doi:10.1080/10408444.2021.1968337
29. International Agency for Research on Cancer. Asbestos (chrysotile, amosite, crocidolite, tremolite, actinolite, and anthophyllite). IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. 2012;100C:219–310.
30. Harris E.J.A., Musk A., de Klerk N., Reid A., Franklin P., Brims F.J.H. Diagnosis of asbestos-related lung diseases. Expert Rev. Respir. Med. 2019;13(3):241–249. doi: 10.1080/17476348.2019.1568875
31. Chen Z., Gaudino G., Pass H.I., Carbone M., Yang H. Diagnostic and prognostic biomarkers for malignant mesothelioma: an update. Transl. Lung Cancer Res. 2017;6(3):259–269. doi: 10.21037/tlcr.2017.05.06
32. Goldberg M., Imbernon E., Rolland P., Gilg Soit Ilg A., Savès M., de Quillacq A., Frenay C., Chamming’s S., Arveux P., Boutin C., Launoy G., … Brochard P. The French national mesothelioma surveillance program. Occup. Environ. Med. 2006;63(6):390–395. doi: 10.1136/oem.2005.023200
33. Schillebeeckx E., van Meerbeeck J.P., Lamote K. Clinical utility of diagnostic biomarkers in malignant pleural mesothelioma: a systematic review and meta-analysis. Eur. Respir. Rev. 2021;30(162):210057. doi: 10.1183/16000617.0057-2021
34. Ferrari L., Carugno M., Mensi C., Pesatori A.C. Circulating epigenetic biomarkers in malignant pleural mesothelioma: state of the art and critical evaluation. Front. Oncol. 2020;10:445. doi: 10.3389/fonc.2020.00445
35. Blyth K.G., Murphy D.J. Progress and challenges in mesothelioma: From bench to bedside. Respir. Med. 2018;134:31–41. doi: 10.1016/j.rmed.2017.11.015
36. Ho M., Bera T.K., Willingham M.C., Onda M., Hassan R., FitzGerald D., Pastan I. Mesothelin expression in human lung cancer. Clin. Cancer Res. 2007;13(5):1571–1575. doi: 10.1158/1078-0432.CCR-06-2161
37. Pantazopoulos I., Boura P., Xanthos T., Syrigos K. Effectiveness of mesothelin family proteins and osteopontin for malignant mesothelioma. Eur. Respir. J. 2013;41(3):706–715. doi: 10.1183/09031936.00226111
38. Grigoriu B.D., Grigoriu C., Chahine B., Gey T., Scherpereel A. Clinical utility of diagnostic markers for malignant pleural mesothelioma. Monaldi Arch. Chest Dis. 2009;71(1):31–38. doi: 10.4081/monaldi.2009.374
39. Lorenzini E., Ciarrocchi A., Torricelli F. Molecular fngerprints of malignant pleural mesothelioma: not just a matter of genetic alterations. J. Clin. Med. 2021;10(11):2470. doi: 10.3390/jcm10112470
40. Creaney J., Dick I.M., Robinson B.W. Discovery of new biomarkers for malignant mesothelioma. Curr. Pulmonol. Rep. 2015;4(1):15–21. doi: 10.1007/s13665-015-0106-8
41. Rossi G., Davoli F., Poletti V., Cavazza A., Lococo F. When the diagnosis of mesothelioma challenges textbooks and guidelines. J. Clin. Med.2021;10(11):2434. doi: 10.3390/jcm10112434
42. Cersosimo F., Barbarino M., Lonardi S., Vermi W., Giordano A., Bellan C., Giurisato E. Mesothelioma malignancy and the microenvironment: molecular mechanisms. Cancers (Basel). 2021;13(22):5664. doi: 10.3390/cancers13225664
43. Wagner J.C., Berry G., Skidmore J.W., Timbrell V. The effects of the inhalation of asbestos in rats. Br. J. Cancer. 1974;29(3):252–269. doi: 10.1038/bjc.1974.65
44. Davis J.M., Beckett S.T., Bolton R.E., Collings P., Middleton A.P. Mass and number of fbres in the pathogenesis of asbestos-related lung disease in rats. Br. J. Cancer. 1978;37(5):673–688. doi: 10.1038/bjc.1978.105
45. Hodgson J.T., Darnton A. The quantitative risks of mesothelioma and lung cancer in relation to asbestos exposure. Ann. Occup. Hyg. 2000;44(8):565–601.
46. Lenters V., Vermeulen R., Dogger S., Stayner L., Portengen L., Burdorf A., Heederik D. A meta-analysis of asbestos and lung cancer: is better quality exposure assessment associated with steeper slopes of the exposure-response relationships? Environ. Health Perspect. 2011;119(11):1547–1555. doi: 10.1289/ehp.1002879 48. Hodgson J.T., Darnton A. Mesothelioma risk from chrysotile. Occup. Environ. Med. 2010;67(6):432. doi: 10.1136/oem.2009.052860
47. Kohyama N., Suzuki Y. Analysis of asbestos fbers in lung parenchyma, pleural plaques, and mesothelioma tissues of North American insulation workers. Ann. N. Y. Acad. Sci. 1991;643:27–52. doi: 10.1111/j.1749-6632.1991.tb24442.x
48. Smith A.H., Wright C.C. Chrysotile asbestos is the main cause of pleural mesothelioma. Am. J. Ind. Med. 1996;30:252–266. doi: 10.1002/(SICI)1097-0274(199609)30:3<252::AID-AJIM2>3.0.CO;2-0
49. Asgharian B., Owen T.P., Kuempel E.D., Jarabek A.M. Dosimetry of inhaled elongate mineral particles in the respiratory tract: The impact of shape factor. Toxicol. Appl. Pharmacol. 2018;361:27–35. doi: 10.1016/j.taap.2018.05.001
50. Coin P.G., Roggli V.L., Brody A.R. Persistence of long, thin chrysotile asbestos fbers in the lungs of rats. Environ. Health Perspect. 1994;102(Suppl 5):197–199. doi: 10.1289/ehp.94102s5197
51. Suzuki Y., Yuen S.R. Asbestos fbers contributing to the induction of human malignant mesothelioma. Ann. N. Y. Acad. Sci. 2002;982:160–176. doi: 10.1111/j.1749-6632.2002.tb04931.x
52. Currie G.P., Watt S.J., Maskell N.A. An overview of how asbestos exposure affects the lung. BMJ. 2009;339:b3209. doi: 10.1136/bmj.b3209
53. Yu C.P., Asgharian B., Pinkerton K.E. Intrapulmonary deposition and retention modeling of chrysotile asbestos fbers in rats. J. Aerosol. Sci. 1991;22:757–763. doi: 10.1016/0021-8502(91)90068-S
54. Ramada Rodilla J.M., Calvo Cerrada B., Serra Pujadas C., Delclos G.L., Benavides F.G. Fiber burden and asbestos-related diseases: an umbrella review. Gac. Sanit. 2022;36(2):173–183. doi: 10.1016/j.gaceta.2021.04.001
55. Stayner L.T., Dankovic D.A., Lemen R.A. Occupational exposure to chrysotile asbestos and cancer risk: a review of the amphibole hypothesis. Am. J. Public Health. 1996;86(2):179–186. doi: 10.2105/ajph.86.2.179
56. Sebastien P., Janson X., Gaudichet A., Hirsch A., Bignon J. Asbestos retention in human respiratory tissues: comparative measurements in lung parenchyma and in parietal pleura. IARC Sci. Publ. 1980;(30):237–246.
57. Dodson R.F., Williams M.G. Jr., Corn C.J.,Brollo A., Bianchi C. Asbestos content of lung tissue, lymph nodes, and pleural plaques from former shipyard workers. Am. Rev. Respir. Dis. 1990;142(4):843–847. doi: 10.1164/ajrccm/142.4.843
58. Gibbs A.R., Stephens M., Grifths D.M.,Blight B.J., Pooley F.D. Fibre distribution in the lungs and pleura of subjects with asbestos related diffuse pleural fbrosis. Br. J. Ind. Med. 1991;48(11):762–770. doi: 10.1136/oem.48.11.762
59. Sekido Y. Molecular pathogenesis of malignant mesothelioma. Carcinogenesis. 2013;34(7):1413–1419. doi: 10.1093/carcin/bgt166
60. Izmerov N.F. Asbestos-caused pathology: diagnosis, clinic, pathomorphology, prevention and rehabilitation. Manual for doctors. Moscow: Research Institute of Occupational Health, 2008. 68 p.
61. Troitskaia N.A. A comparative study of cytotoxicity of dust of carbon fbers and other fbrous materials. Gigiena i sanitariya = Hygiene and Sanitation. 1993;(3):28–30. [In Russian].
62. Kashanskii S.V., Kogan F.M., Malysheva L.G., Zykova V.A. Comparative evaluation of fbrogenesis and toxicity of asbestos-containing heat-proof materials. Meditsina truda i promyshlennaya ekologiya = Occupational Medicine and Industrial Ecology. 1994;(1):17–21. [In Russian].
63. Stayner L.T., Dankovic D.A., Lemen R.A. Asbestos-related cancer and the amphibole hypothesis: II. Stayner and colleagues respond. Am. J. Publ. Health. 1997;87(4):688–689. doi: 10.2105/ajph.87.4.688-a
64. Gaudino G., Xue J., Yang H. How asbestos and other fbers cause mesothelioma. Transl. Lung. Cancer Res. 2020;9(Suppl 1):S39–S46. doi: 10.21037/tlcr.2020.02.01
65. Bernstein D., Dunnigan J., Hesterberg T., Brown R., Velasco J.A., Barrera R., Hoskins J, Gibbs A. Health risk of chrysotile revisited. Crit. Rev. Toxicol. 2013;43(2):154–183. doi: 10.3109/10408444.2012.756454
66. Mossman B.T., Lippmann M., Hesterberg T.W., Kelsey K.T., Barchowsky A., Bonner J.C. Pulmonary endpoints (lung carcinomas and asbestosis) following inhalation exposure to asbestos. J. Toxicol. Environ. Health B. Crit. Rev. 2011;14(1-4):76–121. doi:10.1080/10937404.2011.556047
67. Bernstein D.M. The health effects of short fber chrysotile and amphibole asbestos. Crit. Rev. Toxicol. 2022; 52(2):89–112. doi: 10.1080/10408444.2022.2056430
68. Hillerdal G., Henderson D.W. Asbestos, asbestosis, pleural plaques and lung cancer. Scand. J. Work Environ. Health. 1997;23(2):93–103. doi: 10.5271/sjweh.186
69. Suzuki Y., Yuen S.R., Ashley R. Short, thin asbestos fbers contribute to the development of human malignant mesothelioma: pathological evidence. Int. J. Hyg. Environ. Health. 2005;208(3):201–210. doi: 10.1016/j.ijheh.2005.01.015
70. Frank A.L. Global use of asbestos – legitimate and illegitimate issues. J. Occup. Med. Toxicol. 2020;15:16. doi: 10.1186/s12995-020-00267-y
71. Thives L.P., Ghisi E., Thives Júnior J.J., Vieira A.S. Is asbestos still a problem in the world? A current review. J. Environ. Manage. 2022;319:115716. doi: 10.1016/j.jenvman.2022.115716
72. Ilgren E., van Orden D.R., Lee R.J., Kamiya Y.M., Hoskins J.A. Further studies of Bolivian crocidolite – Part IV: Fibre width, fbre drift and their relation to mesothelioma induction: Preliminary fndings. Epidemiol. Biostat. Public Health. 2015;12:e11167-1. doi: 10.2427/11167
73. Wagner J.C., Berry G., Skidmore J.W., Timbrell V. The effects of the inhalation of asbestos in rats. Br. J. Cancer. 1974;29:252–269. doi: 10.1038/bjc.1974.65
74. Marsili D., Terracini B., Santana V.S., RamosBonilla J.P., Pasetto R., Mazzeo A., Loomis D., Comba P., Algranti E. Prevention of asbestos-related disease in countries currently using asbestos. Int. J. Environ. Res. Public Health. 2016;13(5):494. doi: 10.3390/ijerph13050494
75. Kwak K., Kang D., Paek D. Environmental exposure to asbestos and the risk of lung cancer: a systematic review and meta-analysis. Occup. Environ. Med. 2022;79(3):207–214. doi: 10.1136/oemed-2020-107222
76. Bernstein D.M. The health risk of chrysotile asbestos. Curr. Opin. Pulm. Med. 2014;20(4):366–370. doi: 10.1097/MCP.0000000000000064
77. Pezerat H. Chrysotile biopersistence: the misuse of biased studies. Int. J. Occup. Environ. Health. 2009;15(1):102–106. doi: 10.1179/107735209799449770
78. Guldberg M., Christensen V.R., Perander M., Zoitos B., Koenig A.R., Sebastian K. Measurement of in-vitro fbre dissolution rate at acidic pH. Ann. Occup. Hyg. 1998;42(4):233–243. doi: 10.1016/S0003-4878(98)00026-X
79. di Giuseppe D., Zoboli A., Nodari L., Pasquali L., Sala O., Ballirano P., Malferrari D., Raneri S., Hanuskova M., Gualtieri A.F. Characterization and assessment of the potential toxicity/pathogenicity of Russian commercial chrysotile. American Mineralogist. 2021;106(10):1606–1621. doi: 10.2138/am-2021-7710
80. Calas A., Uzu G., Martins J.M.F., Voisin D., Spadini L., Lacroix T., Jaffrezo J.L. The importance of simulated lung fluid (SLF) extractions for a more relevant evaluation of the oxidative potential of particulate matter. Sci. Rep. 2017;7(1):11617. doi: 10.1038/s41598-017-11979-3
81. Marques M.R.C., Loebenberg R., Almukainzi M. Simulated biological fluids with possible application in dissolution testing. Dissolut. Technol. 2011;8(3):15–28. doi: 10.14227/DT180311P15
82. Larsen G. Experimental data on in vitro fbre solubility. IARC Sci. Publ. 1989;(90):134–139.
83. Finkelstein M.M. Letter to the Editor re Bernstein et al: Health risk of chrysotile revisited. Crit. Rev. Toxicol. 2013;43(8):707–708. doi: 10.3109/10408444.2013.825762
84. Kogan F.M. Modern concept of asbestos safety. Ekaterinburg: ARGO, 1995. 98 p. [In Russian].
85. Elovskaia L.T. Anti-asbestos campaign and conference on “Asbestos and health issues”. Meditsina truda i promyshlennaya ekologiya = Occupational Medicine and Industrial Ecology. 1997;(9):16–21. [In Russian].
86. Kogan F.M., Kashanskii S.V., Plotko E.G., Berzin S.A., Bogdanov G.B. Effect of low concentration of asbestos-containing dust. Meditsina truda i promyshlennaya ekologiya = Occupational Medicine and Industrial Ecology. 1993;(5-6):6–10. [In Russian].
87. Shtol’ A.V., Plotko E.G., Seliankina K.P. Children’s health and environmental air pollution with dust containing asbestos. Meditsina truda i promyshlennaya ekologiya = Occupational Medicine and Industrial Ecology. 2000;(11):10–13. [In Russian].
88. Tsurikova G.V., Spitsyn V.A., Gladkova E.V., Minaeva O.P. Biodemographic parameters as indicators of genetic adaptation to harmful occupational factors (e.g. asbestos). Gigiyena truda i professional’nyye zabolevaniya = Occupational Health and Occupational Diseases. 1992;(6):28–30. [In Russian].
89. Kashanskii S.V., Domnin S.G., Plotko E.G., Kuz’min S.V., Seliankina S.V., Likhacheva E.I. Contemporary problems of asbestos and prospective research directions. Meditsina truda i promyshlennaya ekologiya = Occupational Medicine and Industrial Ecology. 2004;(9):16–18. [In Russian].
90. Krasovskii G.N., Mozhaev E.A. Asbestos in drinking water (review). Gigiena i sanitariya = Hygiene and Sanitation. 1993;(6):20–22. [In Russian].
91. Repina Zh.V., Chemyakina N.A., Tarskaya-Lapteva E.G. Chrysotile cement building materials. Areas of use. Yekaterinburg: AMB, 2009. 151 p. [In Russian].
92. Iatsenko A.S., Kogan F.M., Fomina A.S., Zykova V.A., Nikitina O.V., Vanchugova N.N., Bogdanov G.B., Aliamovskii S.I., Pereliaeva L.A. Correlation between biologic aggression and some physical and chemical properties of industrial dust caused by use of friction tools. Meditsina truda i promyshlennaya ekologiya = Occupational Medicine and Industrial Ecology. 1994;(12):29–33. [In Russian].
93. Kovalevskii E.V. Hygienic evaluation of asbestos-containing friction goods application. Meditsina truda i promyshlennaya ekologiya = Occupational Medicine and Industrial Ecology. 2009;(7):1–6. [In Russian].
94. Iatsenko A.S., Kogan F.M. Occupational morbidity and mortality in malignant neoplasms among persons professionally exposed to asbestos dust. Gigiyena truda i professional’nyye zabolevaniya = Occupational Health and Occupational Diseases. 1990;(2):10–12. [In Russian].
95. Iatsenko A.S., Kogan F.M., El’nichnykh L.N., Remizova I.I. Comparative evaluation of the dust’s fbrinogen activity in asbestos-forming units production. Gigiena i sanitariya = Hygiene and Sanitation. 1991;(8):27–29. [In Russian].
96. Kashanskii S.V. Mesothelioma in Russia: systematic review of 3576 published cases from occupational medicine viewpoint. Meditsina truda i promyshlennaya ekologiya = Occupational Medicine and Industrial Ecology. 2008;(3):15–21. [In Russian].
97. Kashanskii S.V., Zhetpisbaev B.A., Il’derbaev O.Z., Ermenbai O.T. Mesothelioma in the Republic of Kazakhstan: a review. Gigiena i sanitariya = Hygiene and Sanitation. 2008;(5):13–17. [In Russian].
98. Grigorieva L.F., Makarova T.A., Korytkova E.N., Chigareva O.G., Grebenshchikov R.G. Synthetic amphibole asbestos. Leningrad: Nauka; 1975. 250 p. [In Russian].
99. Pylev L.N. The role of modifying factors in the carcinogenic effect of asbestos and asbestos-containing dusts. Eksperimental’naya onkologiya = Experimental Oncology. 1987;9(5):14–17. [In Russian].
100. Pylev D.N., Smirnova O.V., Vasil’eva L.A., Khrustalev S.A., Vezentsev A.I., Gudkova E.A., Naumova L.N. Experimental rationale for carcinogenic risk of asbestos cement industry and its products. Gigiena i sanitariya = Hygiene and Sanitation. 2010;(6):61–65.[In Russian].
101. Jargin S.V. Overestimation of medical consequences of low-dose exposures to ionizing radiation. Sibirskij nauchnyj medicinskij zhurnal = Siberian Scientifc Medical Journal. 2022;42(4):15–32. [In Russian]. doi: 10.18699/SSMJ20220402
102. Bernstein D.M., Toth B., Rogers R.A., Kling D.E., Kunzendorf P., Phillips J.I., Ernst H. Evaluation of the dose-response and fate in the lung and pleura of chrysotile-containing brake dust compared to TiO2, chrysotile, crocidolite or amosite asbestos in a 90-day quantitative Inhal Toxicol study – Interim results Part 2: Histopathological examination, Confocal microscopy and collagen quantifcation of the lung and pleural cavity. Toxicol. Appl. Pharmacol. 2020;387:114847. doi: 10.1016/j.taap.2019.114847
103. Kane A.B., Hurt R.H., Gao H. The asbestos-carbon nanotube analogy: An update. Toxicol. Appl. Pharmacol. 2018;361:68–80. doi: 10.1016/j.taap.2018.06.027
104. Gupta S.S., Singh K.P., Gupta S., Dusinska M., Rahman Q. Do carbon nanotubes and asbestos fbers exhibit common toxicity mechanisms? Nanomaterials (Basel). 2022;12(10):1708. doi: 10.3390/nano12101708
105. Izmerov N.F., Chuchalina A.G. Occupational respiratory organs. A national guide. Moscow: GEOTAR-Media, 2015. 792 p. [In Russian].
106. Shanin N.P., Borodulin M.M., Kolbovsky Yu.Ya. Production of asbestos technical products. Leningrad:Khimia, 1983. 240 p. [In Russian].
Review
Views:
318
Email this article 